TuHURA Biosciences (NASDAQ:HURA) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of TuHURA Biosciences (NASDAQ:HURA) from a sell rating to a hold rating in a research note published on Saturday morning.

A number of other research analysts also recently issued reports on HURA. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. Finally, Maxim Group cut their target price on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, TuHURA Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Price Performance

NASDAQ:HURA opened at $1.90 on Friday. The company’s fifty day moving average price is $1.06 and its 200-day moving average price is $1.70. The firm has a market capitalization of $115.37 million, a P/E ratio of -3.80 and a beta of -0.30. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $4.44.

Institutional Investors Weigh In On TuHURA Biosciences

Several large investors have recently bought and sold shares of the company. Barclays PLC raised its holdings in shares of TuHURA Biosciences by 42.6% during the fourth quarter. Barclays PLC now owns 52,615 shares of the company’s stock valued at $40,000 after acquiring an additional 15,725 shares during the last quarter. State Street Corp boosted its stake in shares of TuHURA Biosciences by 4.9% in the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after acquiring an additional 13,594 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of TuHURA Biosciences by 109.0% in the fourth quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock worth $29,000 after acquiring an additional 19,931 shares during the last quarter. Deutsche Bank AG increased its position in shares of TuHURA Biosciences by 209.8% during the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock worth $61,000 after purchasing an additional 54,051 shares in the last quarter. Finally, Invst LLC increased its position in shares of TuHURA Biosciences by 88.9% during the fourth quarter. Invst LLC now owns 42,506 shares of the company’s stock worth $32,000 after purchasing an additional 20,006 shares in the last quarter. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.